Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Objectives The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV‐experienced patients. Methods RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patien...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2012-07, Vol.13 (6), p.345-351 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 351 |
|---|---|
| container_issue | 6 |
| container_start_page | 345 |
| container_title | HIV medicine |
| container_volume | 13 |
| creator | Bedimo, R Kyriakides, T Brown, S Weidler, J Lie, Y Coakley, E Holodniy, M |
| description | Objectives
The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV‐experienced patients.
Methods
RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12‐week ARV drug‐free period (ARDFP) or initiate immediate salvage therapy (no‐ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations.
Results
In 146 no‐ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P = 0.33 and P = 0.79, respectively) or at week 24 (P = 0.96 and P = 0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P = 0.002, P |
| doi_str_mv | 10.1111/j.1468-1293.2011.00981.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1018344099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1018344099</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3631-38e288f59384f5a3e4e805e73dc40c88febe9c370046f9ebbb32e04b1a6cd5433</originalsourceid><addsrcrecordid>eNqNkbtOxDAQRS0E4v0LyCVNgl9JHIkGIV4SEhRAaznORHiVTYLtLLsdJSXfyJfgsECNG488Z-7I9yKEKUlpPCezlIpcJpSVPGWE0pSQUtJ0uYF2_xqb37VIWJ6zHbTn_YwQWvCSbKMdxliRFyLbRe_3Dmprgl0AXuh2BNw3-Prm6fPtg2IHQ2uNDrbvsNGDNjassO5qPDxD14fVYA32ozcwBFvZdup60zvw2HaRC9ZBcP3COt3i4ECHOXQhKsNyAGehMxClonx89Qdoq9Gth8Ofex89Xl48nF8nt3dXN-dnt4nhOacJl8CkbLKSS9FkmoMASTIoeG0EMbEDFZSGF4SIvCmhqirOgIiK6tzUmeB8Hx2vdQfXv4zgg5rb-IO21R30o1eUUMmFIGUZUblGjeu9d9Cowdm5dqsIqSkHNVOT3WqyW005qO8c1DKOHv1sGas51H-Dv8ZH4HQNvNoWVv8WVjGaWPAvoYCcDg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018344099</pqid></control><display><type>article</type><title>Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>IngentaConnect Free/Open Access Journals</source><source>Wiley Online Library All Journals</source><creator>Bedimo, R ; Kyriakides, T ; Brown, S ; Weidler, J ; Lie, Y ; Coakley, E ; Holodniy, M</creator><creatorcontrib>Bedimo, R ; Kyriakides, T ; Brown, S ; Weidler, J ; Lie, Y ; Coakley, E ; Holodniy, M</creatorcontrib><description>Objectives
The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV‐experienced patients.
Methods
RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12‐week ARV drug‐free period (ARDFP) or initiate immediate salvage therapy (no‐ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations.
Results
In 146 no‐ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P = 0.33 and P = 0.79, respectively) or at week 24 (P = 0.96 and P = 0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P = 0.002, P < 0.001 and P = 0.005, respectively). RC was significantly correlated with dPSS and iPSS at baseline, but did not increase their predictive value. In the 137 ARDFP patients, RC increased significantly (from 52.4 to 85.8%), but did not predict CD4 cell count and viral load changes during ARDFP (P = 0.92 and P = 0.26, respectively). RC after ARDFP did not predict subsequent CD4 cell count and viral load changes 12 weeks following ARV treatment reinitiation (P = 0.90 and P = 0.29, respectively).
Conclusions
We found no additional predictive value of replication capacity for virological or immunological responses (above what PSS provides) in patients undergoing salvage ARV treatment.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/j.1468-1293.2011.00981.x</identifier><identifier>PMID: 22276745</identifier><language>eng</language><publisher>England</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - genetics ; Acquired Immunodeficiency Syndrome - immunology ; Anti-HIV Agents - therapeutic use ; antiretroviral therapy ; CD4 Lymphocyte Count ; Cohort Studies ; Drug Therapy, Combination ; Female ; Genotype ; HIV ; HIV-1 - drug effects ; HIV-1 - physiology ; Humans ; Male ; Middle Aged ; Phenotype ; phenotypic susceptibility score ; Predictive Value of Tests ; Prospective Studies ; replication capacity ; resistance ; RNA, Viral - immunology ; Salvage Therapy - methods ; Treatment Outcome ; Viral Load ; Virus Replication - immunology</subject><ispartof>HIV medicine, 2012-07, Vol.13 (6), p.345-351</ispartof><rights>2012 British HIV Association</rights><rights>2012 British HIV Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3631-38e288f59384f5a3e4e805e73dc40c88febe9c370046f9ebbb32e04b1a6cd5433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1468-1293.2011.00981.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1468-1293.2011.00981.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22276745$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bedimo, R</creatorcontrib><creatorcontrib>Kyriakides, T</creatorcontrib><creatorcontrib>Brown, S</creatorcontrib><creatorcontrib>Weidler, J</creatorcontrib><creatorcontrib>Lie, Y</creatorcontrib><creatorcontrib>Coakley, E</creatorcontrib><creatorcontrib>Holodniy, M</creatorcontrib><title>Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Objectives
The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV‐experienced patients.
Methods
RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12‐week ARV drug‐free period (ARDFP) or initiate immediate salvage therapy (no‐ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations.
Results
In 146 no‐ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P = 0.33 and P = 0.79, respectively) or at week 24 (P = 0.96 and P = 0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P = 0.002, P < 0.001 and P = 0.005, respectively). RC was significantly correlated with dPSS and iPSS at baseline, but did not increase their predictive value. In the 137 ARDFP patients, RC increased significantly (from 52.4 to 85.8%), but did not predict CD4 cell count and viral load changes during ARDFP (P = 0.92 and P = 0.26, respectively). RC after ARDFP did not predict subsequent CD4 cell count and viral load changes 12 weeks following ARV treatment reinitiation (P = 0.90 and P = 0.29, respectively).
Conclusions
We found no additional predictive value of replication capacity for virological or immunological responses (above what PSS provides) in patients undergoing salvage ARV treatment.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - genetics</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>antiretroviral therapy</subject><subject>CD4 Lymphocyte Count</subject><subject>Cohort Studies</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Genotype</subject><subject>HIV</subject><subject>HIV-1 - drug effects</subject><subject>HIV-1 - physiology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Phenotype</subject><subject>phenotypic susceptibility score</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>replication capacity</subject><subject>resistance</subject><subject>RNA, Viral - immunology</subject><subject>Salvage Therapy - methods</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Virus Replication - immunology</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkbtOxDAQRS0E4v0LyCVNgl9JHIkGIV4SEhRAaznORHiVTYLtLLsdJSXfyJfgsECNG488Z-7I9yKEKUlpPCezlIpcJpSVPGWE0pSQUtJ0uYF2_xqb37VIWJ6zHbTn_YwQWvCSbKMdxliRFyLbRe_3Dmprgl0AXuh2BNw3-Prm6fPtg2IHQ2uNDrbvsNGDNjassO5qPDxD14fVYA32ozcwBFvZdup60zvw2HaRC9ZBcP3COt3i4ECHOXQhKsNyAGehMxClonx89Qdoq9Gth8Ofex89Xl48nF8nt3dXN-dnt4nhOacJl8CkbLKSS9FkmoMASTIoeG0EMbEDFZSGF4SIvCmhqirOgIiK6tzUmeB8Hx2vdQfXv4zgg5rb-IO21R30o1eUUMmFIGUZUblGjeu9d9Cowdm5dqsIqSkHNVOT3WqyW005qO8c1DKOHv1sGas51H-Dv8ZH4HQNvNoWVv8WVjGaWPAvoYCcDg</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Bedimo, R</creator><creator>Kyriakides, T</creator><creator>Brown, S</creator><creator>Weidler, J</creator><creator>Lie, Y</creator><creator>Coakley, E</creator><creator>Holodniy, M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients</title><author>Bedimo, R ; Kyriakides, T ; Brown, S ; Weidler, J ; Lie, Y ; Coakley, E ; Holodniy, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3631-38e288f59384f5a3e4e805e73dc40c88febe9c370046f9ebbb32e04b1a6cd5433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - genetics</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>antiretroviral therapy</topic><topic>CD4 Lymphocyte Count</topic><topic>Cohort Studies</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Genotype</topic><topic>HIV</topic><topic>HIV-1 - drug effects</topic><topic>HIV-1 - physiology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Phenotype</topic><topic>phenotypic susceptibility score</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>replication capacity</topic><topic>resistance</topic><topic>RNA, Viral - immunology</topic><topic>Salvage Therapy - methods</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Virus Replication - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bedimo, R</creatorcontrib><creatorcontrib>Kyriakides, T</creatorcontrib><creatorcontrib>Brown, S</creatorcontrib><creatorcontrib>Weidler, J</creatorcontrib><creatorcontrib>Lie, Y</creatorcontrib><creatorcontrib>Coakley, E</creatorcontrib><creatorcontrib>Holodniy, M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bedimo, R</au><au>Kyriakides, T</au><au>Brown, S</au><au>Weidler, J</au><au>Lie, Y</au><au>Coakley, E</au><au>Holodniy, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2012-07</date><risdate>2012</risdate><volume>13</volume><issue>6</issue><spage>345</spage><epage>351</epage><pages>345-351</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Objectives
The aim of the study was to determine the prognostic value of HIV replication capacity (RC) for subsequent antiretroviral (ARV) treatment response in ARV‐experienced patients.
Methods
RC and phenotypic resistance testing were performed at baseline and week 12 on plasma samples from patients randomized to undergo a 12‐week ARV drug‐free period (ARDFP) or initiate immediate salvage therapy (no‐ARDFP group) in the Options in Management with Antiretrovirals (OPTIMA) trial. Dichotomous and incremental phenotypic susceptibility scores (dPSSs and iPSSs, respectively) were calculated. The predictive value of RC and PSS for ARV therapy response and/or ARDFP was evaluated using multivariate regression analysis and Pearson correlations.
Results
In 146 no‐ARDFP subjects, baseline RC (50.8%) did not change at week 12 and was not correlated with CD4 cell count or viral load changes at week 12 (P = 0.33 and P = 0.79, respectively) or at week 24 (P = 0.96 and P = 0.14, respectively). dPSS predicted virological but not CD4 cell count response to ARV therapy at weeks 12, 24 and 48 (P = 0.002, P < 0.001 and P = 0.005, respectively). RC was significantly correlated with dPSS and iPSS at baseline, but did not increase their predictive value. In the 137 ARDFP patients, RC increased significantly (from 52.4 to 85.8%), but did not predict CD4 cell count and viral load changes during ARDFP (P = 0.92 and P = 0.26, respectively). RC after ARDFP did not predict subsequent CD4 cell count and viral load changes 12 weeks following ARV treatment reinitiation (P = 0.90 and P = 0.29, respectively).
Conclusions
We found no additional predictive value of replication capacity for virological or immunological responses (above what PSS provides) in patients undergoing salvage ARV treatment.</abstract><cop>England</cop><pmid>22276745</pmid><doi>10.1111/j.1468-1293.2011.00981.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2012-07, Vol.13 (6), p.345-351 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1018344099 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; IngentaConnect Free/Open Access Journals; Wiley Online Library All Journals |
| subjects | Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - genetics Acquired Immunodeficiency Syndrome - immunology Anti-HIV Agents - therapeutic use antiretroviral therapy CD4 Lymphocyte Count Cohort Studies Drug Therapy, Combination Female Genotype HIV HIV-1 - drug effects HIV-1 - physiology Humans Male Middle Aged Phenotype phenotypic susceptibility score Predictive Value of Tests Prospective Studies replication capacity resistance RNA, Viral - immunology Salvage Therapy - methods Treatment Outcome Viral Load Virus Replication - immunology |
| title | Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A43%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictive%20value%20of%20HIV%E2%80%901%20replication%20capacity%20and%20phenotypic%20susceptibility%20scores%20in%20antiretroviral%20treatment%E2%80%90experienced%20patients&rft.jtitle=HIV%20medicine&rft.au=Bedimo,%20R&rft.date=2012-07&rft.volume=13&rft.issue=6&rft.spage=345&rft.epage=351&rft.pages=345-351&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/j.1468-1293.2011.00981.x&rft_dat=%3Cproquest_cross%3E1018344099%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018344099&rft_id=info:pmid/22276745&rfr_iscdi=true |